Phase Ib study of PRT543, an oral protein arginine methyltransferase 5 (PRMT5) inhibitor, in patients with advanced splicing factor-mutant myeloid malignancies.

ABSTRACT:

SUBMITTER: Bewersdorf JP 

PROVIDER: S-EPMC11879867 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature